Definitive Healthcare Corp. Stock Price, News & Analysis

Definitive Healthcare Corp. (Nasdaq: DH) has appointed Jon Maack as President effective November 3, 2022. Maack, who brings extensive experience in healthcare SaaS, will oversee product management, engineering, corporate strategy, and M&A, reporting to CEO Robert Musslewhite. Maack previously served as Chief Strategy Officer at athenahealth and held senior roles at Optum and Bain & Company. He expressed excitement about joining Definitive Healthcare, emphasizing the untapped potential in the healthcare commercial intelligence market as they aim to enhance tools for their customer base of over 3,000.

Definitive Healthcare Corp. (Nasdaq: DH) reported a 33% year-over-year revenue growth to $57.4 million for Q3 2022. The net loss narrowed to ($6.4) million from ($21.0) million in Q3 2021, representing 11% of revenue. Adjusted net income rose to $8.9 million with adjusted EBITDA at $16.4 million, or 29% of revenue. The company continues to gain traction with new customers and product launches, including Passport Express. For Q4 2022, it expects revenue between $58-59 million, a 26% increase year-over-year.

Definitive Healthcare Corp. (Nasdaq: DH) will release its third-quarter financial results for the period ending September 30, 2022, on November 3, 2022, after market close. A conference call and webcast to discuss these results will take place at 5:00 PM ET. Investors can access a live audio webcast on the company’s Investor Relations website. A replay will be available until November 17, 2022. Definitive Healthcare specializes in healthcare commercial intelligence, helping clients navigate market opportunities through its SaaS platform.

Definitive Healthcare (Nasdaq: DH) announced its commitment to the UN Global Compact, the largest corporate sustainability initiative globally, aimed at aligning operations with ten principles covering human rights, labor, environment, and anti-corruption.

CEO Robert Musslewhite emphasized the company's dedication to community betterment and transparency in sustainability efforts. The company also focuses on diversity, equity, and inclusion, enhancing hiring processes and engaging employees in community service through its DefinitiveCares program, while minimizing its environmental impact.

Definitive Healthcare announces a significant change in its Board of Directors, with Sastry Chilukuri joining as a member on September 30, 2022, while Randy Winn departs. Chilukuri, co-CEO of Medidata, brings over 22 years of experience in healthcare technology, expected to enhance the company's leadership in the life sciences sector. CEO Robert Musslewhite expressed optimism about Chilukuri’s contributions. Winn played a vital role in expanding the client base to over 3,000 and supporting the company through its recent IPO.

Definitive Healthcare Corp. (Nasdaq: DH) announced participation in two key conferences: the 2022 Baird Global Healthcare Conference in New York and the Goldman Sachs Communacopia + Technology Conference in San Francisco. CEO Robert Musslewhite will present on September 13, 2022, at 12:15 PM ET, while Executive Chairman Jason Krantz and CFO Rick Booth will present on September 14, 2022, at 5:15 PM PT (8:15 PM ET). Both presentations will be webcasted live, and replays will be accessible for a limited time on the investor relations website.

Definitive Healthcare (Nasdaq: DH) reported a 37% year-over-year revenue growth in Q2 2022, reaching $54.5 million. The net loss improved to ($9.6) million, representing 18% of revenue, compared to 38% in the previous year. Adjusted net income rose to $8.9 million, with an adjusted EBITDA of $16.3 million, or 30% of revenue. Cash flow from operations stood at $15.5 million or 28% of revenue. For Q3 2022, the company expects revenue between $56.0 – $57.0 million.

Definitive Healthcare Corp. (Nasdaq: DH) announced that its leadership team will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 9:30 a.m. Eastern Time. The presentation, featuring Founder Jason Krantz, CEO Robert Musslewhite, and CFO Rick Booth, aims to highlight the company’s innovations in healthcare commercial intelligence. A live webcast will be available on the investor relations website, with a replay accessible for a limited time.

Definitive Healthcare specializes in transforming data into insights for clients navigating the healthcare market.

Definitive Healthcare (Nasdaq: DH) has launched Passport Express, integrating analytical data from Analytical Wizards with extensive therapy-specific data. This new product enhances biopharma pre-launch planning across 20 therapy areas, providing vital commercial intelligence to accelerate market performance.

Passport Express offers ready-to-use analytics with up to seven interactive dashboards focused on market and brand dynamics, treatment pathways, and patient compliance. The aim is to simplify data sourcing for biopharma companies, ensuring up-to-date information is readily accessible.